A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This trial will enroll patients that have been diagnosed with a transient ischemic attack
(TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a
minor stroke faces the possibility of long-term disability and even death, regardless of
treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or
worsen over the hours or days immediately following a stroke. TEMPO-2 is a minor stroke trial
for patients presenting within 12 hours of their symptom onset. Patients will be randomized
to TNK-tPA or standard of care. In the intervention group TNK-tPA is given as a single,
intravenous bolus (0.25mg/Kg) immediately upon randomization. Maximum dose 50mg. The control
group will receive antiplatelet agent(s) as decided by the treating physician. Antiplatelet
agent(s) choice will be at the treating physician's discretion.
TEMPO-2 Coordinating Centre is located in Calgary, AB, Canada. There will be approximately 50
sites participating worldwide.
Dr. Shelagh Coutts is the Principal Investigator.